Picture of Euroapi SA logo

EAPI — Euroapi SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapValue Trap

France's EuroAPI H1 net sales fall on product discontinuations

France's EuroAPI H1 net sales fall on product discontinuations


Overview

  • France API maker's H1 net sales fell 13.5% yr/yr, driven by product discontinuations

  • Core EBITDA margin dropped to 5.8% from 9.6% as cost savings offset by lower activity

  • Company agreed to sell Brindisi site to Huvepharma as part of transformation plan


Outlook

  • EuroAPI expects FY 2026 net sales to be in line with initial outlook

  • Company now sees FY 2026 Core EBITDA margin at around 6% due to FX impact

  • EuroAPI expects FY 2026 CAPEX to be about 8% of net sales


Result Drivers

  • PRODUCT DISCONTINUATIONS - Co said planned discontinuation of APIs as part of portfolio optimization negatively impacted sales by €13 mln

  • LOWER SALES TO SANOFI AND OTHER CLIENTS - Co attributed revenue decline to reduced API Solutions sales to Sanofi (down 36.2%) and other clients (down 11.0%), notably due to lower corticosteroids and complex small molecules sales

  • COST SAVINGS OFFSET BY LOWER ACTIVITY - Co said lower personnel expenses and external cost savings were more than offset by impact of lower manufacturing activity on industrial performance


Company press release: ID:nGNE6PcFD4


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Sales

EUR 356.50 mln

H1 Net Loss

EUR 141.50 mln

H1 Adjusted EBITDA

EUR 20.70 mln

H1 Gross Margin

15.70%

H1 EBITDA

-EUR 43.10 mln


Analyst Coverage

  • The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Euroapi SA is €1.60, about 29% above its July 28 closing price of €1.24


Reuters Recommended Reads

  • July 28 - Germany's Medios cuts 2026 EBITDA outlook on pharma supply price pressure

  • July 29 - Teva Pharm profit misses estimates, seeks US tariff details


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Euroapi SA

See all news